12:00 AM
 | 
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Arcalyst rilonacept regulatory update

FDA's Arthritis Advisory Committee voted 11-0 that efficacy and safety data do not support approval of Arcalyst rilonacept from Regeneron to prevent gout flares in adults initiating uric acid-lowering therapy. The panel voted 6-5 that...

Read the full 155 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >